Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
ERIS Lifesciences
Mid Cap•3,620 Employees•IPO 2017
Current Price
₹1321.10
-30.5 (-2.26%)Updated
Today's Range
1310
₹1321.10
1353
52 Week Range
52W Low₹1097.20
52W High₹1910.00
₹1321.10
Downside20.41%
Upside44.58%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹18,163.16 Cr
Market Cap
Total market value of companyP/E Ratio
42.11
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
6.99
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹31.61
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
7.19%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
12.20%
ROCE
Return on Capital Employed. >15% is goodNet Margin
14.01%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
3.59%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
21.92%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
7.40%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
41.60%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.87
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹209.63
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
54.80%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
3 points- •ERIS Lifesciences boasts a strong operating profit margin (OPM) of 35.40%, showcasing efficient operations and high profitability. A Return on Equity (ROE) of 12.90% indicates effective capital utilization and superior returns for shareholders.
- •The company demonstrates impressive quarterly profit growth, achieving a remarkable 41.60% increase. This positive trend, alongside a 7.40% rise in quarterly sales, signifies a healthy expansion trajectory within the pharmaceuticals sector.
Weaknesses
4 points- •ERIS's debt-to-equity ratio of 0.87 suggests a relatively high debt level compared to equity. This could heighten financial risk, particularly during economic downturns, potentially limiting financial flexibility and impacting strategic decisions.
- •The stock's Price-to-Earnings (PE) ratio of 57.40 is high, indicating a potentially overvalued stock relative to its earnings. This valuation makes it vulnerable to corrections if earnings growth doesn't meet investor expectations.
Opportunities
3 points- •Operating within the robust Pharmaceuticals and Healthcare sectors, ERIS is well-positioned to capitalize on increasing healthcare expenditure, rising chronic disease prevalence, and growing demand for quality medicines.
- •The impressive 41.60% quarterly profit growth indicates strong underlying demand and potential for further market share expansion. Strategic product diversification or new market entry could accelerate this growth trajectory.
Threats
4 points- •The recent stock price volatility, with a 52-week high of ₹1910 and a low of ₹1097, presents a risk for investors seeking stability. This fluctuation underscores market uncertainty and potential for capital loss.
- •While promoter holding is high at 54.85%, any significant future decrease could signal waning confidence in the company's prospects. This could negatively impact investor sentiment and share price, requiring continuous monitoring.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1432.07 | +₹110.97 | +8.40% |
| R3 | ₹1389.07 | +₹67.97 | +5.14% |
| R2 | ₹1371.03 | +₹49.93 | +3.78% |
| R1 | ₹1346.07 | +₹24.97 | +1.89% |
| PIVOT | ₹1328.03 | 6.93 | 0.52% |
| CURRENT | ₹1321.10 | - | - |
| S1 | ₹1217.07 | -₹104.03 | -7.87% |
| S2 | ₹1260.07 | -₹61.03 | -4.62% |
| S3 | ₹1285.03 | -₹36.07 | -2.73% |
| S4 | ₹1303.07 | -₹18.03 | -1.37% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+25.8% vs avg
0.93L
(13 Mar 2026)Delivery %+10.8% vs avg
69.3%
(13 Mar 2026)Avg Volume (20D)20-day average
0.74L
(13 Feb - 13 Mar)Avg Delivery %Trend ↑
58.6%
(13 Feb - 13 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Acutaas Chemicals Ltd
93.50 %
Highest Dividend Yield
Pfizer Ltd
3.28 %
Peer Comparison
| Company Name |
|---|
 Acutaas Chemicals Ltd |
 Alembic Pharmaceuticals Ltd |
 Astrazeneca Pharma India Ltd |
 Caplin Point Laboratories Ltd |
 Concord Biotech Ltd |
 Emcure Pharmaceuticals Ltd |
 Granules India Ltd |
 J B Chemicals & Pharmaceuticals Ltd |
 Jubilant Pharmova Ltd |
 Natco Pharma Ltd |
 Neuland Laboratories Ltd |
 Pfizer Ltd |
 Piramal Pharma Ltd |
 Sun Pharmaceutical Industries Ltd |
 Wockhardt Ltd |
About
ERIS Lifesciences Ltd
Eris Lifesciences Limited is a pharmaceutical company headquartered in Ahmedabad, India, that focuses on providing domestically branded formulations for chronic and sub-chronic therapeutic treatments within the Indian market. Their business model centers on developing and marketing a wide range of branded medications across several key therapeutic areas.
The company's product portfolio covers a diverse spectrum of medical needs. This includes treatments for anti-diabetes, cardiovascular diseases, dermatological conditions, neurological disorders, gynecological issues, nephrological problems, and oncology. Additionally, they offer products focused on central nervous system health, women's health, and nutritional supplements like vitamins and minerals.
Beyond just medication, Eris Lifesciences also provides various patient care services to enhance healthcare access and management. These services include ambulatory blood pressure and electrocardiogram monitoring, continuous glucose monitoring, sleep studies, and antenatal care solutions. This integrated approach differentiates them in the market by offering a more holistic patient experience.
Eris Lifesciences distributes its products through a well-established network encompassing wholesale drug distributors, stockists, and retail pharmacies, ensuring wide accessibility across India. This robust distribution network is a key component of their strategy for reaching a broad patient base and maintaining market presence.
Founded in 2007, Eris Lifesciences has built a significant presence in the Indian pharmaceutical market through its commitment to providing affordable and effective medications combined with supportive patient care services. Their focus on chronic and sub-chronic therapies signifies a dedication to addressing the long-term health needs of a considerable segment of the population.
COMPANY FACTS - ERIS
Registered Address
Shivarth Ambit, Plot No 142/2,, Ramdas Road, Off SBR,, Near Swati Bungalows, Bodakdev,
Ahmedabad
GUJARAT
IN
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 3,620
IPO Date: 29/06/2017
MANAGEMENT - ERIS
Mr. Amit Bakshi
Executive Chairman of the Board, Managing Director
Mr. Sachin Shah
Chief Financial Officer
Mr. Krishnakumar Vaidyanathan
Chief Operating Officer, Executive Director
Mr. Milind Talegaonkar
Compliance Officer, Company Secretary
Mr. Inderjeet Negi
Executive Director
Mr. Kaushal Shah
Executive Director
Mr. Rajeev Dalal
Non-Executive Independent Director
Mr. Prashant Gupta
Non-Executive Independent Director
Ms. Kalpana Unadkat
Non-Executive Independent Director
Mr. Sujesh Vasudevan
Non-Executive Independent Director
Investor Questions Answered
ERIS Lifesciences Ltd (ERIS) Stock FAQs
Get answers to the most common questions about ERIS Lifesciences Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of ERIS Lifesciences Ltd (ERIS) is ₹1,321.1. Today, the stock has declined by ₹30.50 (2.26%), trading in a range of ₹1,310 to ₹1,353. The stock opened at ₹1,341.5 with a trading volume of 93,073 shares.
ERIS Lifesciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹18,163.16 crores, P/E ratio of 42.11, ROE of 7.19%, and ROCE of 12.20%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of ERIS Lifesciences Ltd (ERIS) is ₹1,910, while the 52-week low is ₹1,097.2. Currently trading at ₹1,321.1, the stock is 27.5% away from its 52-week low and 30.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy ERIS Lifesciences Ltd stock at ₹1,321.1 depends on multiple factors. The stock is currently trading with a P/E ratio of 42.11 and P/B ratio of N/A. Today's performance shows a loss of 2.26%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
ERIS Lifesciences Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,321.1, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
ERIS Lifesciences Ltd's key financial metrics include: P/E Ratio: 42.11, P/B Ratio: N/A, ROE: 7.19%, ROCE: 12.20%, Dividend Yield: 0.00%, EPS: ₹31.61, Book Value: ₹209.63, Debt-to-Equity: 0.87, and Current Ratio: N/A. The company's market cap stands at ₹18,163.16 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
ERIS Lifesciences Ltd stock opened at ₹1,341.5 and is currently trading at ₹1,321.1, showing a decline of ₹30.50 (2.26%). The intraday high is ₹1,353 and low is ₹1,310. The trading volume stands at 93,073 shares, indicating moderate market participation today.
ERIS Lifesciences Ltd has a Price-to-Earnings (P/E) ratio of 42.11, which means investors are willing to pay ₹42.11 for every ₹1 of earnings. With an EPS of ₹31.61, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
ERIS Lifesciences Ltd has a market capitalization of ₹18,163.16 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,321.1) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
ERIS Lifesciences Ltd has a book value of ₹209.63 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,321.1, which is 530.2% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
ERIS Lifesciences Ltd has a Return on Equity (ROE) of 7.19% and Return on Capital Employed (ROCE) of 12.20%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
ERIS Lifesciences Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
ERIS Lifesciences Ltd has a debt-to-equity ratio of 0.87, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
ERIS Lifesciences Ltd has an Earnings Per Share (EPS) of ₹31.61, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,321.1 and P/E ratio of 42.11, investors are paying 42.11 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
ERIS Lifesciences Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
ERIS Lifesciences Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze ERIS Lifesciences Ltd stock, consider: 1) Fundamental Analysis - Review P/E (42.11), ROE (7.19%), debt-to-equity (0.87), and growth rates. 2) Technical Analysis - Check 52-week range (₹1097.20 - ₹1910.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1321.10) with book value (₹209.63) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of ERIS Lifesciences Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,321.1 is 132010x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in ERIS Lifesciences Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1097.20 - ₹1910.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.87 indicates leverage. 4) Liquidity Risk - Based on trading volume of 93,073 shares. 5) Valuation Risk - P/E of 42.11 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
ERIS Lifesciences Ltd operates in the industry with key metrics: P/E ratio of 42.11, ROE of 7.19%, market cap of ₹18,163.16 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.87), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for ERIS Lifesciences Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,321.1, with a 52-week range of ₹1097.20 to ₹1910.00. Based on fundamentals like P/E (42.11), ROE (7.19%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling ERIS Lifesciences Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1321.10. 2) Fundamental Deterioration - Declining ROE (currently 7.19%), increasing debt (D/E: 0.87), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for ERIS Lifesciences Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu